An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ozari Health, a company that helps connect people with telehealth services, published an online “GLP-1 provider checklist” for 2026. In plain terms, they put out a guide aimed at doctors and clinics that prescribe GLP-1 drugs (the class that includes medications like Ozempic and Wegovy). The announcement is a company press release describing the checklist and making it available on their website. GLP-1 drugs are a type of medicine that mimic a natural hormone called glucagon-like peptide-1. That hormone helps control blood sugar and also reduces appetite and slows stomach emptying. Drugs in this group—often called GLP-1 receptor agonists—are used for type 2 diabetes and for weight management. People commonly hear brand names like Ozempic or Wegovy, but the checklist is about the broader class of treatments and how providers should handle prescribing and monitoring them. What the company released is a practical resource for clinicians: a list of steps or best practices for prescribing GLP-1 therapies through online or telehealth services. The press release doesn’t present new clinical data or claim a medical breakthrough. It’s an operational tool meant to help providers follow safe and consistent procedures—things like patient screening, dosing schedules, follow-up plans, and documentation. Because this is a company-issued checklist, it’s intended to reflect Ozari Health’s standards and may be influenced by their business model and the regulations they follow. This matters because GLP-1 drugs have become much more widely used in recent years, and many people are getting prescriptions through telemedicine. A standard checklist can help reduce variability between providers and make sure patients get basic safety checks and clear follow-up. If you or someone you know is seeking a GLP-1 prescription online, a provider using a checklist like this might be more likely to check for things such as other medications, medical history, and plans for monitoring side effects. There are caveats. A company checklist is not the same as official clinical guidelines from medical societies or regulatory approval changes. The checklist reflects one company’s approach and may not cover every clinical nuance. Also, it doesn’t replace individualized medical judgement; not every patient fits a template. GLP-1 drugs themselves can cause side effects such as nausea, gastrointestinal upset, and in rare cases more serious issues; they should be prescribed and monitored by qualified clinicians. Finally, the press release does not provide evidence that using the checklist improves outcomes—just that the checklist exists. Bottom line: Ozari Health has published a practical checklist for clinicians who prescribe GLP-1 drugs via telehealth, which could help standardize care—though it’s a company resource, not new medical evidence or a formal guideline.
Source: GlobeNewswire